Adult Immunization

Infectious disease physician Amesh Adalja, MD, explains how PCPs can reframe vaccines as health technology to boost confidence and counter hesitancy.

Amesh Adalja, MD, explains how physicians can rebut social media vaccine claims with concise, referenced facts and patient-centered communication.

Dr Adalja offers evidence-based strategies to address patient concerns about aluminum and thimerosal in vaccines.

The prefilled syringe presentation streamlines administration of the vaccine, eliminating the need to combine the lyophylized antigen and separate adjuvant.

GSK's RSV vaccine Arexvy would join shots from Pfizer and Moderna for the younger adult population, broadening choice for those with risk factors for severe disease.

The adult vaccine market is poised for explosive growth, with more than 100 product launches expected over the next 10 years. Are US clinicians ready?

CD388, an investigational nonvaccine antiviral, demonstrated efficacy up to 76% against influenza in a cohort of more than 5000 healthy, unvaccinated adults.

The vaccine showed superior relative vaccine efficacy that was 26.6% higher than a licensed standard-dose influenza vaccine, Moderna reported.

FDA panel endorses continued use of monovalent JN.1 strain for COVID-19 vaccines, aligning with global health recommendations amid evolving variants.

Moderna voluntarily withdrew the BLA after consultation with the FDA and will resubmit once it has additional phase 3 efficacy data for its investigational flu shot.